Sanofi: FDA accepts Dupixent (dupilumab) for review in children with moderate-to-severe asthma
FDA accepts Dupixent (dupilumab) for review in children with moderate-to-severe asthma Submission supported by data demonstrating Dupixent significantly reduced severe asthma attacks and is the on… FinanzNachrichten.de: Bestbewertete Nachrichten
